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Introduction: Prognostic evaluation of bronchioloalveolar carci-
noma (BAC) from a homogenous population of Caucasian patients.
Methods: Retrospective analysis of resected BAC reclassified ac-
cording to the 2004 World Health Organization classification of lung
tumors. Analyzed variables are clinicoradiologic presentation, his-
tologic subtypes, stage, epidermal growth factor receptor (EGFR)
and HER2/neu immunohistochemical expression, EGFR exons 18,
19, and 21 mutations, K-RAS exon 2 mutation. Univariate and
multivariate analyses of survival were performed.
Results: Of 40 patients analyzed, EGFR and HER2/neu expression
were detected in 72% and 20%, respectively. HER2/neu expression
significantly characterized mucinous BAC (46% versus 7%; p 
0.014). EGFR mutations were identified in 17% (30% in nonmuci-
nous BAC and none in mucinous BAC; p  0.083). K-RAS muta-
tions were found in 42.5% (92% in mucinous BAC versus 18% in
other types; p  0.0001). Early stages (IAIB) nonmucinous BAC
had excellent prognosis: 5 years overall survival of 91% (100% for
stage IA). Sixty six percent (4 of 6) of patients with multifocal
disease died (two mucinous BAC and one nonmucinous BAC with
recurrent disease). Seventy one percent (5 of 7) of patients with
pneumonic-like tumor (all mucinous BAC) died of recurrent/pro-
gressive disease. Stage (p  0.004) and histologic classifications
(p  0.035) resulted as independent prognostic factors at multivar-
iate analysis.
Conclusions: Early stage nonmucinous BAC has excellent progno-
sis, whereas mucinous BAC presents a poor prognosis. Locally
advanced nonmucinous BAC has a poor prognosis: the diagnosis of
nonmucinous BAC in large tumors should be interpreted with
caution given the possible presence of invasive areas in incom-
pletely sampled tumor. Coexpression of EGFR and HER2/neu in
mucinous BAC could be considered for future trials on target
therapies even in Caucasian population.
(J Thorac Oncol. 2010;5: 830–836)
Bronchioloalveolar carcinoma (BAC) is considered a sub-type of pulmonary adenocarcinoma presenting unique
clinical and pathologic features. The latest 2004 World
Health Organization (WHO) and the International Associa-
tion for the Study of Lung Cancer (IASLC) classifications of
lung tumors define BAC as an adenocarcinoma without
stromal, pleural, or blood vessels infiltration.1 These strict
criteria have lead to a significant cultural change in the
relationship between adenocarcinoma and BAC. Most of
tumors diagnosed as BAC before the release of the current
WHO classification were instead invasive adenocarcinomas
with some percentage of BAC component at the tumor
periphery and should now be correctly reclassified as mixed
acinar adenocarcinoma with BAC features.2 BAC, according
to the current strict histologic diagnostic criteria, represents
an exceedingly rare neoplasm if we consider that what was
previously called BAC only accounted for 2 to 5% of all
nonsmall cell lung carcinoma (NSCLC).1,2 Therefore, it is
incorrect to compare results of studies on BAC before and
after the third edition of the classification of lung tumors.
Recently, attempts have been made to classify small periph-
eral adenocarcinomas into subgroups according to the pattern
of tumor growth,3 and the presence of BAC features seems to
predict prognosis in mixed adenocarcinoma.3–6 Despite these
recent evidences, the real prognosis of BAC tumors diag-
nosed according to the current 2004 WHO classification is
still controversial, and in particular, the prognostic value of
BAC subtypes (nonmucinous BAC versus mucinous BAC
versus mixed subtype BAC) and the relationship among
pathologic features, clinicoradiologic presentation, and re-
sponse to surgical treatment are still unclear. Moreover,
molecular evaluation of these tumors has revealed a signifi-
cant difference between nonmucinous BAC and mucinous
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BAC which seem as two distinct entities, in particular, when
K-RAS and epidermal growth factor receptor (EGFR) alter-
ations are considered.7 These genes are deeply involved in
early molecular stages of pulmonary adenocarcinogenesis,
show mutually exclusive mutation, and are significantly as-
sociated with BAC subtypes and patients clinicopathologic
features.7,8 Of note, clinicopathologic and genetic results on
BAC mainly derive from studies on East Asian population,
but it is suggested that several differences between Caucasian
and Asian ethnicity may exist.7,8
The aim of this single-institution retrospective study is
to investigate the prognostic effect of the current 2004 WHO
histologic classification in surgically resected BAC tumors in
a population of Caucasian patients. We also analyze the
prognostic role of clinicopathologic features and genetic
abnormalities of K-RAS and EGFR.
PATIENTS AND METHODS
Files from the archives of the Section of Pathologic
Anatomy of the University of Modena and Reggio Emilia
were retrospectively reviewed to retrieve all the patients with
a diagnosis of BAC of the lung who underwent surgical
resection at the Division of Thoracic Surgery of the Univer-
sity of Modena and Reggio Emilia between January 1995 and
December 2007. All the slides of these selected patients were
then reviewed by two pathologists of our group (G.R. and
E.T.) and reclassified according to the diagnostic criteria set
by the 2004 WHO classification of lung tumor,1in which
BAC is defined as a “growth of neoplastic cells along preex-
isting alveolar structures (lepidic growth) without evidence of
stromal, vascular, or pleural invasion.” Three BAC subtypes
were recognized as follows: mucinous, nonmucinous, and
mixed types. All the cases analyzed consisted of surgical
specimens that were routinely fixed in 10% buffered forma-
lin. After gross examination, the sampled tissues were em-
bedded in paraffin blocks. Complete sampling of tumor areas
was performed in 34 of 40 cases, whereas six cases were
incompletely examined because of the large size the tumor
occupying almost the entire pulmonary lobe. A mean of four
(range, 2–12) hematoxylin and eosin-stained slides per tumor
was available. In doubtful cases of pleural invasion, histo-
chemical stain for elastic fibers (Weigert and/or Van Gieson
stains) was performed. All the patients were Caucasian and
no East Asian cases were present in the study population.
For all patients, the following clinical and pathologic
features were recorded: age at diagnosis, gender, smoking
history (never smokers—lifetime exposure to 100 ciga-
rettes; former smokers—patients quit smoking 3 years
before diagnosis; and current active smokers), clinicoradio-
logic presentation at imaging evaluation (solitary, multifocal,
or pneumonic), surgical procedure, postoperative mortality
(within 30 days from the surgical procedure), pathologic
staging, EGFR and HER2/neu immunohistochemical expres-
sion, EGFR and K-RAS genes mutations. All the patients
were staged according to the 1997 International Association
for the Study of Lung Cancer/Union Internationale Contre le
Cancer Tumor, Node, Metastasis staging system.9 Patients
with an indeterminate tumor size because of a pneumonic-
like presentation were staged as TX. Patients with multiple
nodules of the same tumor histologic type in the same lobe
were classified as IIIB, whereas multiple nodules in different
lobes were considered as stage IV. Complete resection was
defined as removal of the primary tumor and all accessible
hilar and mediastinal lymph nodes with no residual neoplastic
tissue left. Anatomic resection was considered as the standard
procedure for all cases. Minor resections were reserved for
patients with compromised pulmonary function. All the pa-
tients underwent mediastinal lymph node dissection. No pa-
tient underwent adjuvant therapy with EGFR tyrosine kinase
inhibitors.
Clinical and follow-up data were collected from patho-
logic reports, clinical charts, referring physicians, or directly
from the patients’ families. This is a retrospective descriptive
study, and all information was collected and used to perform
anonymous and aggregate statistical analysis. The institu-
tional review board of Policlinico of Modena has approved
this study.
Immunohistochemical Analysis
The antibodies used in the study and their technical
characteristics are the following: EGFR (prediluted; protease
pretreatment; clone 31G7; Ventana, Tucson, AZ) and HER2/
neu (1:150 dilution; microwave; clone CB11; Novocastra,
Newcastle upon Tyne, UK). Negative and positive controls
were included in each batch. For each antibody, the percent-
age of positive cells and the intensity of staining (0: negative;
1: weak; 2: moderate; and 3: strong) were recorded. A
tumor was considered positive when at least 20% of the
neoplastic cells reacted with a 2 or higher intensity on the
relevant subcellular localization (cytoplasmic and/or mem-
branous).
DNA Extraction and Sequencing Analysis
Molecular analysis of EGFR exons 18, 19, and 21 and
K-RAS exon 2 was performed by direct sequencing polymer-
ase chain reaction as described in a previous study by our
group10 and in both forward and reverse directions.
Statistical Analysis
The descriptive analysis was expressed in terms of
frequency, median and SD. Frequencies were compared with
the 2 test, for categorical variables; Fisher exact test was
used for small samples. t test and analysis of variance were
performed when comparing continuous variables. The overall
and disease-free survivals were calculated according to the
Kaplan-Meier method. Deaths from noncancer-related causes
were considered as withdrawals. Date of death or recurrence
represented the end points of follow-up for each type of
survival analysis. Univariate analysis of overall and disease-
free survivals was performed using the log-rank test. Vari-
ables resulting statistically significant at univariate analysis
were evaluated in a multivariate analysis using Cox regres-
sion models. A probability value of less than 0.05 was
considered statistically significant.
RESULTS
Of 1468 patients with a diagnosis of NSCLC who
underwent surgical resection with curative intent in the ana-
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lyzed period, a total of 127 cases (9%) were initially col-
lected. After histologic review at multiheaded microscope, 87
cases resulted as mixed acinar invasive adenocarcinoma with
BAC features and were not included in the statistical analysis
(pleural invasion and stromal invasion was present in 16 and
71 cases, respectively). Forty patients (3% of all NSCLC
resected in the analyzed period) with a BAC diagnosis com-
plying with current diagnostic criteria were finally evaluated
(Figures 1A–C). Clinical, pathologic, and genetic features of
the patients are listed in Table 1. Mean age was 65 years
(median 66, SD 7.91, range 37–80 years). No postoperative
death was reported.
Significant correlations between histologic classifica-
tion, pathologic stage, clinical presentation, and genetic ab-
normalities were recorded and summarized in Table 2. Non-
mucinous BAC presents more frequently in a solitary form
(p  0.012) at an early stage (p  0.004), whereas mucinous
BAC is more frequently associated to a multifocal disease or
a pneumonic-like clinical pattern (p  0.012) in more ad-
vanced stages (p  0.004). Overall, EGFR and HER2/neu
expression were noted in 72% and 20%, respectively. How-
ever, EGFR expression did not seem to be significantly
associated to BAC subtypes (Figure 1D), whereas HER2/neu
expression significantly characterized mucinous BAC (46%
versus 7% in the other types; p  0.014; Figure 1E). Overall,
EGFR mutations were identified in 17% (six exon 21 mis-
sense and one exon 19 deletion mutations), whereas K-RAS
mutations were found in 42% of BAC (eight G12C; five
G12V; three G12D; one G12A). As reported in Table 2, the
mutation profile was significantly different in the histologic
subtypes. EGFRmutations were also strongly related to never
smoking status (57% versus 9%; p  0.002) and in female
gender (29% versus 8%, p 0.05). No significant correlation
was found among K-RAS mutation, gender, and smoking
habit.
FIGURE 1. Example of a nonmucinous BAC (A, hematoxy-
lin and eosin; original magnification, 155), mucinous BAC
(B, hematoxylin and eosin; original magnification, 100),
mixed BAC (C, hematoxylin and eosin; original magnifica-
tion, 155). Positive immunostaining for EGFR in a nonmu-
cinous BAC (D, EGFR, immunohistochemistry, magnification
155), and HER2/neu in a mucinous BAC (E, HER2/neu, im-
munohistochemistry, magnification 100).
TABLE 1. Patients Characteristics
Variable No. of Patients (%)
Gender
Male 23 (57)
Female 17 (43)
Smoking history
Current 29 (73)
Former 4 (10)
Never 7 (17)
Clinical presentation
Solitary 27 (66)
Multifocal 6 (15)
Pneumonic 7 (19)
Surgical procedure
Lobectomy 30 (75)
Pneumonectomy 1 (2)
Wedge resection 9 (23)
pStage
IA 12 (30)
IB 12 (30)
IIA 1 (2)
IIB 1 (2)
IIIA 1 (2)
IIIB 2 (5)
IV 4 (10)
TX 7 (19)
Histological classification
Nonmucinous 20 (50)
Mucinous 13 (32)
Mixed 7 (18)
EGFR expression
Positive 29 (72)
Negative 11 (28)
HER2/neu expression
Positive 8 (20)
Negative 32 (80)
EGFR mutation
No mutation 33 (83)
Exon 18 0
Exon 19 1 (2)
Exon 21 6 (15)
RAS mutation
No mutation 23 (57.5)
Exon 2 17 (42.5)
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Analysis of Survival
Follow-up was completed for all patients by December
2008 (median 48 months, range from 2 to 132 months). For
all patients, the overall 5 years survival rate was 64%, with a
median survival time of 69 months. Five years disease-free
survival was 51% with a median disease-free survival time of
28 months.
Nineteen patients (48%) developed tumor recurrences/
metastases after pulmonary resection: pulmonary recurrenc-
es/metastases in 14 patients (35%) and metastases in ex-
trathoracic sites in five patients (12%: three brain, one bone,
and one liver metastases). All the patients who developed
extrapulmonary metastases resulted incompletely sampled at
gross examination. Ten patients (25%: four nonmucinous
BAC, four mucinous BAC, and two mixed BAC) with soli-
tary intrathoracic recurrence underwent a second surgical
resection. Five years overall survival of reoperated patients
was 60% (four patients died of a second recurrence: three
mucinous BAC and one mixed BAC).
Overall, 18 patients died during the follow-up period:
four patients (all with nonmucinous BAC) without disease
recurrence died because of lung noncancer-related causes,
and 14 patients (eight mucinous BAC, three nonmucinous
BAC, and three mixed BAC) died of recurrent-progressive
disease. Five patients with recurrent disease (three nonmuci-
nous BAC, one mucinous BAC, and one mixed BAC) were
alive at the end of the follow-up.
At univariate analysis of survival, clinicoradiologic
presentation, pathologic stage, and histologic pattern signifi-
cantly affected overall and disease-free survivals (Figures
2A–D). The 5 years overall and disease-free survival for
solitary lesions were 73% and 63%, for multifocal lesions
50% and 25%, and for pneumonic-like tumors 28% and 28%,
respectively (p 0.048 for overall survival and p 0.051 for
disease-free survival). The 5 years overall and disease-free
survival for mucinous BAC were 44% and 35%, for nonmu-
cinous BAC 81% and 67%, and for mixed BAC 47% and
28%, respectively (p  0.021 for overall survival and p 
0.016 for disease-free survival). The 5 years overall and
disease-free survival were 79% and 69%, respectively for
stage IAIB, 34% and 28% for advanced stages (p  0.006
for overall survival and p  0.020 for disease-free survival).
Other clinical (age, gender, type of surgery, and smok-
ing habit), immunohistochemical (EGFR and HER2/neu ex-
pression), and genetic (EGFR and K-RAS mutations) vari-
ables were not significantly related to survival at univariate
analysis. However, a trend toward better overall survival was
recorded for patients with EGFR mutations (5 years overall
survival of 80% for EGFR mutation and 56% for absence of
EGFR mutation, p  0.064) and for patients without K-RAS
mutation (5 years overall survival of 52% for absence of
K-RAS mutation and 76% for K-RAS mutation, p  0.065).
Within solitary forms, 5 years overall survival for
stages IA and IB was 91% and 69%, respectively. No survival
analysis could be computed for solitary stages II and IIIA
because of a limited number of cases (three patients). Sur-
vival analysis according to histologic patterns in solitary
forms at early stages (IA and IB) revealed a significantly
increased overall and disease-free survivals for nonmucinous
BAC compared with mucinous BAC and mixed BAC (Fig-
ures 2G, H). In solitary early stage (stages IA and IB), the 5
years overall survival and disease-free survival were 91% and
74% respectively for nonmucinous BAC, and 66% and 45%
for mucinous BAC/mixed BAC (p  0.044 for overall sur-
vival and p  0.042 for disease-free survival). In particular,
the 10 patients with stage IA solitary nonmucinous BAC were
all alive at the end of follow-up (5 years overall survival of
100%).
The small subgroup of patients with multifocal disease
and pneumonic-like disease (six and seven, respectively) did
not allow a reliable analysis of survival. Four of six patients
(66%) with multifocal tumor died (two mucinous BAC and
one nonmucinous BAC for recurrent disease and one nonmu-
cinous BAC for noncancer-related cause). Two patients with
multifocal mixed BAC were alive at 37 and 47 months after
surgery, one with a recurrent disease. Five of seven patients
(71%) with pneumonic-like BAC died of recurrent pulmo-
nary disease. All these patients had mucinous BAC. One
patient with mucinous pneumonic-like BAC was alive with-
out disease at 72 months and one patient with nonmucinous
pneumonic-like BAC was alive with recurrent disease at 77
months.
All the clinical and pathologic variables that resulted
significantly related to survival at univariate analysis were
examined in a multivariate analysis (Table 3). Stage (p 
0.004) and histologic classifications (p  0.035) were con-
firmed as independent prognostic factors affecting overall
survival, whereas no variable resulted significantly related to
disease-free survival.
TABLE 2. Correlation Between 2004 WHO Histological
Classification and Clinical Presentation, Pathological Stage,
and Molecular Setup for EGFR and KRAS Mutations
Variable
Histologic Subtypes, No. of Patients (%)
pMucinous Nonmucinous Mixed
Clinical presentation 0.012
Solitary 5 (38) 17 (85) 5 (71)
Multifocal 2 (16) 2 (10) 2 (29)
Pneumonic 6 (46) 1 (5)
pStage 0.004
IA 1 (8) 10 (50) 1 (14)
IB 4 (30) 5 (25) 3 (43)
IIAIIBIIIA 2 (10) 1 (14)
IIIB 2 (29)
IV 2 (16) 2 (10)
TX 6 (46) 1 (5)
EGFR mutation 0.083
No mutation 13 (100) 14 (70) 6 (86)
Exon 18
Exon 19 1 (5)
Exon 21 5 (25) 1 (14)
RAS mutation 0.001
No mutation 1 (7) 17 (85) 5 (71)
Exon 2 12 (93) 3 (15) 2 (29)
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DISCUSSION
The definition of pulmonary adenocarcinoma and the
concept of BAC in particular are still matter of debate and
investigation among surgeons, radiologists, clinicians, and
pathologists too,1,2 namely for the following reasons: (a) the
epidemiologic changes of lung cancer incidence with adeno-
carcinomas greatly overriding other histotypes11; (b) the dis-
covery of somatic EGFR and K-RAS mutations in adenocar-
cinomas with significant impact on treatment with targeted
therapies against EGFR12,13; (c) the new histologic definition
of BAC as a noninvasive lung cancer, with the possible
intrinsic curative significance once completely resected1,3;
and (d) the emerging clinicopathologic, molecular, and pos-
sibly therapeutical models of lung adenocarcinogenesis ac-
cording to patient’s gender and smoking status.12–14 The
results of our study confirm that even in the Caucasian
population the current concept of BAC involves at least two
distinct and unrelated tumor entities with peculiar clinicora-
diologic presentation and molecular and prognostic features.
The nonmucinous BAC subtype usually presents as a solitary
lesion or more rarely with multiple lesions or pneumonic-like
expression. The prognosis for this subtype of BAC tumor is
usually favorable even though our survival results are lower
than those previously reported by Japanese authors.3–5 This
discrepancy can be explained by the different selection cri-
teria and morphologic classification adopted. Our retrospec-
tive study includes a relatively large amount of advanced
stage cases, whereas the surgical series by Japanese authors
usually derive from computed tomography screening pro-
grams where only representing early stages of the disease. In
our experience, a significant percentage of locally advanced
nonmucinous BAC presented extrapulmonary metastases. As
suggested in the 2004 WHO classification, the diagnosis of
nonmucinous BAC should not only be based on surgical
specimens but also the tumor should be completely sampled
to avoid invasion. In our experience, six tumors of large size
were not entirely sampled. The retrospective design of this
study did not allow evaluation of further blocks of these
incompletely sampled neoplasms. In these cases, the avail-
able blocks showed a BAC tumor, but the presence of
FIGURE 2. Kaplan-Meier survival curves. A, Overall survival for clinical pattern (p  0.048); B, Overall survival for BAC histo-
logic subtype (p  0.021); C, Overall survival for pathologic stage (p  0.006); D, Solitary early stages (stages IA and IB; p 
0.044).
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invasion cannot be reasonably excluded. Five of six patients
experienced extrapulmonary metastases. This finding raises
the issue on the importance of gross examination in diagnos-
ing BAC. Moreover, Japanese authors adopted the Noguchi’s
classification system,3 in which type A and B peripheral
(replacing type) adenocarcinomas showed an excellent prog-
nosis after surgical resection. The prognosis of early stages
nonmucinous BAC of our surgical series reflects these re-
sults, with a 5-year overall survival of 100% for stage IA and
91% for stage IB because of one nonlung cancer-related
death. In our surgical series, no patient with an early stage
nonmucinous BAC died of a cancer-related cause. Early
stages nonmucinous BAC diagnosed according the 2004
WHO criteria have the same excellent prognosis of types A
and B Noguchi’s peripheral adenocarcinoma. Based on these
promising results, some authors advocate limited resection
without mediastinal lymph nodes dissection for these tumors
when they are more than 2 cm of diameter.15–17 In our series,
only nine patients with compromised pulmonary function
underwent limited resections. Although, at univariate analysis
of survival, the prognosis of these patients did not signifi-
cantly differ from that of patients treated with major resec-
tion, definitive conclusions on the ideal type of resection
cannot be drawn from the current small series of BAC. Until
the results of ongoing Japanese trials on limited resection for
peripheral lesions are available, major pulmonary resections
with mediastinal lymph nodes dissection should be consid-
ered the gold standard for these lesions.
Recent studies have demonstrated no survival differ-
ences after surgery between solitary and multifocal nonmu-
cinous BAC.18 Although only two cases (5%) of multifocal
nonmucinous BAC are present in our series, we suggest that
such tumors should be surgically treated whenever possible
because satisfactory results can be obtained when BAC has a
nonmucinous component. In general, BAC presents pulmo-
nary recurrences (usually ipsilateral) more frequently than
other types of NSCLC.17 The optimal management of recur-
rent disease is still debated. In our series, 25% of patients
experienced a pulmonary recurrence and was reoperated with
good survival results. In such cases, limited resections should
be preferred considering the high rate of expected pulmonary
recurrences that should be subsequently amenable of reop-
eration.
Mucinous and mixed BAC usually present as pneumo-
nic-like masses. Patients with pneumonic-like BAC generally
present a poor prognosis after surgery,19 with a high percent-
age of patients early developing pulmonary recurrences and/
or, more rarely, distant metastases. Moreover, recurrences are
usually not amenable of reoperation. In our series, 71% of
patients showing a pneumonic-like mucinous BAC died of
respiratory failure because of widespread pulmonary involve-
ment, therefore supporting the idea that tumor cell aeroge-
nous spread throughout the alveoli should be considered as an
invasive factor similar to what happens in pleura, stroma, or
blood vessels. Basically, mucinous BAC could remain a
variant of an invasive form of adenocarcinoma according to
the current classification of lung cancer. This issue supports
the diagnostic criteria proposed in the new classification of
lung adenocarcinoma recently presented at the 13th World
Congress of Lung Cancer.20
The hypothesis that mucinous BAC and nonmucinous
BAC are two clear-cut distinct entities is strongly supported
by their entirely different immunoprofile, obtained using a
panel of diagnostic markers (TTF-1, cytokeratins 7 and 20,
MUC2 and MUC5, and surfactant protein),21 and their quite
peculiar molecular setup for EGFR and K-RAS genes muta-
tions, indicating two different pathways of oncogenesis.8,22–25
As confirmed by a sound body of evidence,7,8,22,23,26 also in
our study EGFR mutations were significantly identified in
nonmucinous BAC (30%), whereas K-RAS mutations char-
acterized mucinous BAC (92%). As expected, even non-
smoking status and female gender were strongly related to
EGFR mutations, whereas tumors in smoking men had a
significant association with K-RAS mutations.7,8 The high
ratio of EGFR exon 21/exon 19 mutations detected in our
study could somehow appear in discrepancy with that com-
monly reported in similar studies. However, an equal distri-
bution of EGFR mutations on exons 19 and 21 has been
reported in a large series of NSCLC by Marchetti et al,24
whereas Hsieh et al.25 found EGFR exon 21 and exon 19
mutations in 76% and 17%, respectively, analyzing a series of
35 adenocarcinomas. In addition, our study reported an in-
teresting and significant association between HER2/neu ex-
pression and mucinous BAC. Although genetic profiles have
not revealed a significant prognostic impact in our series, all
these observations basically point out that the concept of
TABLE 3. Multivariate Cox Survival Analysis According to Stage, Histologic
Classification, and Clinical Presentation
Variable
Overall Survival Disease Free Survival
HR (CI 95%) p HR (CI 95%) p
Clinical presentation
Solitary vs. multifocal/pneumonic 0.205 (0.033–1.251) 0.086 0.652 (0.050–8.369) 0.249
Pathologic stage
IA and IB vs. others 0.066 (0.010–0.429) 0.004 0.685 (0.191–2.458) 0.416
Histologic classification
nmBAC vs. mBAC/mixedBAC 0.223 (0.055–0905) 0.035 0.403 (0.046–3.353) 0.542
HR, hazard ratio.
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BAC currently includes at least two different oncogenetic
pathways. These results could be considered in future trials
aimed at evaluating specific target therapies for different
histologic subtypes of BAC.
Given the unavoidable limitations because of the ret-
rospective design of our study, definitive conclusions cannot
be drawn. However, some key messages emerged from our
results. BAC diagnosed according to the current WHO clas-
sification are rare lung tumors in the routine practice, ac-
counting for approximately 2% of all resected NSCLC, and
their histologic subtypes represent independent prognostic
factors. The definition of BAC, when appropriately applied
on histologic analysis, includes different entities with differ-
ent clinical, pathologic, and genetic features possibly leading
to different prognosis and therapeutic approaches. As previ-
ously reported in several works from East Asia, early stage
nonmucinous BAC can be cured with surgical resection alone
in almost all cases, presenting an acceptable prognosis even
when pulmonary recurrences are surgically treated. However,
we point out that the diagnosis of BAC requires the evalua-
tion of the entire surgical specimen. This issue can present
some pitfalls in the diagnosis of large size tumors, which
ultimately lead to unexpected poor survival results in locally
advanced nonmucinous BAC. Mucinous BAC presents a
poor prognosis after surgical resection because of the high
local recurrence rate leading to respiratory failure. The aerog-
enous spread along the alveoli characterizing mucinous BAC
(or “mucinous adenocarcinoma with lepidic pattern,” as pro-
posed by the new IASLC/American Thoracic Society/Euro-
pean Respiratory Society classification of lung adenocarcino-
mas) should be considered as a morphologic component of
invasive parameters. Given the close association between
K-RAS mutations and mucinous BAC, and the significant
combined expression of EGFR and HER2/neu in this sub-
type, an alternative approach using humanized monoclonal
antibodies against EGFR and/or HER2/neu could be evalu-
ated in future trials including mucinous BAC.
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